首页 / 院系成果 / 成果详情页

Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study 期刊论文

编号：

9651D943798B31322A6A48792F74EF7E
作者：

Fan, Huishou#^[1]Feng, XiangYan#^[2]Wei, Rongxia#^[2]Zhang, Xin^[3];Li, Tianlan^[1];Liu, Lu(刘璐)^[4]Wang, Hui^[1];Sun, Lingjie^[1];Shi, Xue^[1];Zhao, Hongguo^[1];Li, Zhao(李召)^[4]Cui, Jingying^[3];Xu, Junqing^[2];Ma, Junjie(马俊杰)^[2]Feng, Xianqi^[1];Wang, Wei*^[1]
语种：

英文
期刊：

THERAPEUTIC ADVANCES IN HEMATOLOGY ISSN：2040-6207 2026 年 17 卷
收录：
关键词：

multiple myeloma relapsed and refractory proteasome inhibitor safety survival outcomes
摘要：

Background: Relapsed and refractory multiple myeloma (RRMM) is generally associated with a poor prognosis. Objectives: This real-world study aims to evaluate the efficacy and safety of the carfilzomib-pomalidomide-dexamethasone (KPd) regimen in patients with RRMM. Design: A multicenter, retrospective study was conducted in four centers in China. Methods: RRMM patients who received at least 1 cycle of KPd across four centers were retrospectively included and stratified by prior lines of treatment, survival outcomes and safety profile were analyzed. Results: A total of 82 patients were enrolled. Based on the lines of treatment (LOT) at KPd initiation, patients were stratified into second-line (2L, n=39), third-line (3L, n=26), and fourth-line or beyond (4L+, n=17) groups. Among 72 response-evaluable patients, the overall response rate (ORR) was 69.4%, with ORRs of 79.4%, 73.9%, and 40.0% in the 2L, 3L, and 4L+ groups, respectively. After a median follow-up of 10.8 months, the median progression-free survival (mPFS) for the entire cohort was 22.5 months, while the median overall survival (mOS) was not reached (NR). The mPFS was NR, 22.5, and 10.1 months (P=0.178), and the mOS was NR, NR, and 11.6 months (P=0.019) for patients receiving KPd in the 2L, 3L, and 4L+ settings, respectively. Multivariable analysis identified elevated lactate dehydrogenase (LDH) level (HR=3.489, 95% CI: 1.557-7.823) and LOT >= 4 (HR=2.791, 95% CI: 1.086-7.177) as independent predictors of inferior PFS (P<0.05), while LOT >= 4 (HR=3.917, 95% CI: 1.258-12.200) was also associated with worse OS (P=0.019). Grade >= 3 adverse events (AEs) occurred in 12.8%, 50.0%, and 47.1% of patients in the 2L, 3L, and 4L+ groups, respectively. Conclusion: The KPd regimen demonstrated favorable clinical efficacy and manageable toxicity in RRMM, particularly in those with early-line relapse.
推荐引用方式
GB/T 7714：

Fan Huishou,Feng XiangYan,Wei Rongxia, et al. Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study [J].THERAPEUTIC ADVANCES IN HEMATOLOGY,2026,17.
APA：

Fan Huishou,Feng XiangYan,Wei Rongxia,Zhang Xin,&Wang Wei.(2026).Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study .THERAPEUTIC ADVANCES IN HEMATOLOGY,17.
MLA：

Fan Huishou, et al. "Real-world efficacy and safety of the carfilzomib-pomalidomide-dexamethasone regimen in patients with relapsed/refractory multiple myeloma: A multicenter retrospective study" .THERAPEUTIC ADVANCES IN HEMATOLOGY 17(2026).
入库时间：

9/2/2026 10:07:39 PM
更新时间：

9/3/2026 12:23:44 AM

浏览次数：3  下载次数：0

分享到：

浏览次数：3

下载次数：0

打印次数：0